AstraZeneca Does Not Expect Crestor Labeling Change Following Fatality
This article was originally published in The Pink Sheet Daily
Executive Summary
The company says that a fatality potentially caused by rhabdomyolysis appeared in spontaneous adverse event reporting for the cholesterol-lowering drug. AstraZeneca maintains that the evidence concerning the cause of death is more consistent with neuroleptic malignant syndrome.
You may also be interested in...
AstraZeneca’s Crestor Label Revised With Stronger Rhabdomyolysis Warnings
Labeling now emphasizes increased risk of rhabdomyolysis, especially at 40 mg dose, but FDA reaffirms that muscle toxicity is seen across the statin class and is not unique to rosuvastatin. Labeling also recommends caution in dosing in patients of Asian descent due to increased elevation in rosuvastatin exposure.
AstraZeneca’s Crestor Label Revised With Stronger Rhabdomyolysis Warnings
Labeling now emphasizes increased risk of rhabdomyolysis, especially at 40 mg dose, but FDA reaffirms that muscle toxicity is seen across the statin class and is not unique to rosuvastatin. Labeling also recommends caution in dosing in patients of Asian descent due to increased elevation in rosuvastatin exposure.
Pfizer's Celebrex Showed Cardiovascular Risk In 1999 Alzheimer's Study
A study of celecoxib in Alzheimer's disease patients showed a statistically significant increase in cardiovascular events versus placebo. The study data are posted on PhRMA's clinicalstudyresults.org website, but Public Citizen alleges Pfizer recently revised the posting and questions when the data were submitted to FDA.